{"entity":{"id":"nct04183712","kind":"trial","name":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA","aka":[],"tldr":"A phase 2 trial of gemcitabine, oxaliplatin and afatinib in gallbladder cancer, run by Shanghai Jiao Tong University School of Medicine, now recruiting.","summary":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA is a phase 2, randomised interventional study registered as NCT04183712 by Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 102 participants, started 2020-06-01 and due to reach its primary completion in 2025-06. Interventions recorded: gemcitabine and oxaliplatin., Afatinib. Conditions listed: Gallbladder Carcinoma. Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04183712","url":"https://clinicaltrials.gov/study/NCT04183712"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","kinase-inhibitors"],"targets":[],"drugs":["gemcitabine","oxaliplatin","afatinib"],"companies":[],"institutions":[],"pathways":[],"terms":["ctdna"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04183712","phase":"2","setting":"A Multicentre, Open-label, Randomised, Controlled Study of Target Therapy Based on Tumor Molecular Profiling With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA.","sponsor":"Shanghai Jiao Tong University School of Medicine","enrolled":102,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04183712/","neighbours":{"cancer":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}